The Expanding Role of Digital Therapeutics in the Post-COVID-19 Era

Amit Dang1, *, Dimple Dang1, Pawan Rane2
1 MarksMan Healthcare Communications, Hyderabad, Telangana, India
2 Healthway Hospital, Goa, India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 5281
Abstract HTML Views: 1230
PDF Downloads: 1095
ePub Downloads: 447
Total Views/Downloads: 8053
Unique Statistics:

Full-Text HTML Views: 2624
Abstract HTML Views: 651
PDF Downloads: 776
ePub Downloads: 278
Total Views/Downloads: 4329

Creative Commons License
© 2021 Dang et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Founder and CEO, KYT Adhere; Founder and CEO, MarksMan Healthcare Communications, Hyderabad, Telangana, India; Tel: +91 77383 89300; Email:


One of the few positive outcomes of the ongoing COVID-19 pandemic is that it has enhanced the pace of digitalisation of healthcare. Among various facets of digital health, Digital Therapeutics (DTx) is unique as it offers evidence-based interventions for preventing, managing, or treating specific disorders. It is different from wellness apps because it requires evidence from a clinical trial or real-world settings and is bound by regulatory approval and clearance. The DTx market is expected to grow exponentially in the post-COVID era, and there are multiple drivers for the same. After the onset of the pandemic, the viewpoint of various stakeholders of the DTx market, including the patients, prescribers, payers, and pharma industry, have changed significantly. Regulatory bodies have also started to realise the importance of DTx. This review provides an overview of the present status and future potential of DTx considering the COVID-19 pandemic.

Keywords: Digital therapeutics, COVID-19, DTx market, DTx regulations, mHealth, Digital health.